Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections

키워드

참고문헌 (61)

1. Paterson DL, "Extended-spectrum beta-lactamases: a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
2. Livermore DM, "Bacterial resistance: origins, epidemiology, and impact", Clin Infect Dis, 36(Suppl 1), pp.S11~S23 (2003)
3. Rupp ME, "Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment", Drugs, 63, pp.353~365 (2003)
4. Picozzi SC, "Extended-spectrum beta-lactamase-positive Escherichiacoli causing complicated upper urinary tract infection: urologist should act in time", Urol Ann, 6, pp.107~112 (2014)
5. Jacoby GA, "The new beta-lactamases", N Engl J Med, 352, pp.380~391 (2005)
6. Kliebe C, "Evolution of plasmid-coded resistance to broad-spectrum cephalosporins", Antimicrob Agents Chemother, 28, pp.302~307 (1985)
7. Singer RS, "Antibiotic resistance--the interplay between antibiotic use in animals and human beings", Lancet Infect Dis, 3, pp.47~51 (2003)
8. Ambler RP, "A standard numbering scheme for the class A beta-lactamases", Biochem J, 276(Pt 1), pp.269~270 (1991)
9. Bush K, "A functional classification scheme for beta-lactamases and its correlation with molecular structure", Antimicrob Agents Chemother, 39, pp.1211~1233 (1995)
10. Dhillon RH, "ESBLs: a clear and present danger", Crit Care Res Pract (2012)[DOI]
11. Bradford PA, "Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat", Clin Microbiol Rev, 14, pp.933~951 (2001)
12. Salverda ML, "Natural evolution of TEM-1 β-lactamase: experimental reconstruction and clinical relevance", FEMS Microbiol Rev, 34, pp.1015~1036 (2010)
13. Heritage J, "Evolution and spread of SHV extended-spectrum beta-lactamases in gram-negative bacteria", J Antimicrob Chemother, 44, pp.309~318 (1999)
14. Tzouvelekis LS, "CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes", Int J Antimicrob Agents, 14, pp.137~142 (2000)
15. Sun Y, "High prevalence of bla(CTX-M) extended-spectrum β-lactamase genes in Escherichia coli isolates from pets and emergence of CTX-M-64 in China", Clin Microbiol Infect, 16, pp.1475~1481 (2010)
16. Cantón R, "The CTX-M beta-lactamase pandemic", Curr Opin Microbiol, 9, pp.466~475 (2006)
17. Clinical and Laboratory Standards Institute (CLSI), "CLSI document M100-S25" (2015), CLSI
18. "Breakpoint tables for interpretation of MICs and zone diameters: version 5.0" (2015)[URL]
19. Hombach M, "Effects of clinical breakpoint changes in CLSI guidelines 2010", 2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli, 2012, pp.67, 622~632
20. Pitout JD, "Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern", Lancet Infect Dis, 8, pp.159~166 (2008)
21. Arlet G, "Molecular characterisation by PCR-restriction fragment length polymorphism of TEM beta-lactamases", FEMS Microbiol Lett, 134, pp.203~208 (1995)
22. Randegger CC, "Real-time PCR and melting curve analysis for reliable and rapid detection of SHV extendedspectrum beta-lactamases", Antimicrob Agents Chemother, 45, pp.1730~1736 (2001)
23. Bonnet R, "Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes", Antimicrob Agents Chemother, 48, pp.1~14 (2004)
24. Reinert RR, "Antimicrobial susceptibility among organisms from the Asia", Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline, 2007, pp.60, 1018~1029
25. Bell JM, "Prevalence of extended spectrum betalactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99)", Diagn MicrobiolInfect Dis, 42, pp.193~198 (2002)
26. Hawkey PM, "Prevalence and clonality of extended-spectrum beta-lactamases in Asia", Clin Microbiol Infect, 14(Suppl 1), pp.159~165 (2008)
27. Pai H, "The characteristics of extended-spectrum beta-lactamases in Korean isolates of Enterobacteriaceae", Yonsei Med J, 39, pp.514~519 (1998)
28. 이학민, "Frequency of Extended-spectrum b-lactamase (ESBL) and AmpC b-lactamase Genes in Escherichia coli and Klebsiella pneumoniae over a Three-year Period in a University Hospital in Korea", Annals of Laboratory Medicine, 30(6), pp.616~623 (2010), 대한진단검사의학회
29. 이동섭, "Prevalence and Risk Factors for Extended Spectrum Beta-Lactamase-Producing Uropathogens in Patients with Urinary Tract Infection", Investigative and Clinical Urology, 51(7), pp.492~497 (2010), 대한비뇨기과학회
30. Kang CI, "Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains", J Clin Microbiol, 50, pp.312~317 (2012)
31. Paterson DL, "Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases", Clin Infect Dis, 39, pp.31~37 (2004)
32. Paterson DL, "Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory", J Clin Microbiol, 39, pp.2206~2212 (2001)
33. Endimiani A, "Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin", Clin Infect Dis, 38, pp.243~251 (2004)
34. Mohr JF, "Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections", Clin Infect Dis, 47(Suppl 1), pp.S41~S51 (2008)
35. Kaniga K, "Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacinresistant Enterobacteriaceae: analysis of six phase 3 clinical studies", Antimicrob Agents Chemother, 54, pp.2119~2124 (2010)
36. Papp-Wallace KM, "Carbapenems: past, present, and future", Antimicrob Agents Chemother, 55, pp.4943~4960 (2011)
37. Jacoby G, "Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens", Antimicrob Agents Chemother, 41, pp.1830~1831 (1997)
38. Lee NY, "Cefepime therapy for monomicrobial bacteremia caused by cefepimesusceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters", Clin Infect Dis, 56, pp.488~495 (2013)
39. Thomson KS, "Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae", Antimicrob Agents Chemother, 45, pp.3548~3554 (2001)
40. Zanetti G, "Cefepime Study Group. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study", Antimicrob Agents Chemother, 47, pp.3442~3447 (2003)
41. Endimiani A, "Cefepime: a reappraisal in an era of increasing antimicrobial resistance", Expert Rev Anti Infect Ther, 6, pp.805~824 (2008)
42. Jones RN, "Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study", Diagn Microbiol Infect Dis, 19, pp.33~38 (1994)
43. Chopra T, "Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli", Antimicrob Agents Chemother, 56, pp.3936~3942 (2012)
44. Harris PN, "β-lactam and β-lactamase inhibitor combinations in the treatment of extendedspectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options", Lancet Infect Dis, 15, pp.475~485 (2015)
45. Bonfiglio G, "Inoculum effects on Etests and agar dilution minimum inhibitory concentrations. Piperacillin and piperacillin-tazobactam against Staphylococcus aureus", Diagn Microbiol Infect Dis, 19, pp.163~166 (1994)
46. Chaubey VP, "Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae", BMC Res Notes, 3, pp.116~ (2010)
47. Zarkotou O, "Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment", Clin Microbiol Infect, 17, pp.1798~1803 (2011)
48. Shepherd AK, "Management of urinary tract infections in the era of increasing antimicrobial resistance", Med Clin North Am, 97, pp.737~757 (2013)
49. Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)
50. Gupta K, "Management of urinary tract infections from multidrug-resistant organisms", Infect Dis Clin North Am, 28, pp.49~59 (2014)
51. Grabe M, "Guidelines on urological infections", European Association of Urology, ~ (2015)
52. Lichtenberger P, "Complicated urinary tract infections", Curr Infect Dis Rep, 10, pp.499~504 (2008)
53. Pallett A, "Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gramnegative bacteria", J Antimicrob Chemother, 65(Suppl 3), pp.iii25~iii33 (2010)
54. Grif K, "In vitro activity of fosfomycin in combination with various antistaphylococcal substances", J Antimicrob Chemother, 48, pp.209~217 (2001)
55. Falagas ME, "Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials", J Antimicrob Chemother, 65, pp.1862~1877 (2010)
56. Rosso-Fernández C, "FOREST Study Group. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigatordriven randomised controlled trial", BMJ Open, 5, pp.e007363~ (2015)
57. Prakash V, "Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases", Antimicrob Agents Chemother, 53, pp.1278~1280 (2009)
58. Ramphal R, "Extended-spectrum beta-lactamases and clinical outcomes: current data", Clin Infect Dis, 42(Suppl 4), pp.S164~S172 (2006)
59. Beytur A, "Oral amoxicillin-clavulanic Acid treatment in urinary tract infections caused by extended-spectrum Beta-lactamase-producing organisms", Jundishapur J Microbiol, 8, pp.e13792~ (2014)
60. de La Blanchardière A, "Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β- lactamase-producing Enterobacteriaceae", Med Mal Infect, 45, pp.169~172 (2015)
61. Boucher HW, "nfectious Diseases Society of America. 10 x '20 Progress: development of new drugs active against gramnegative bacilli: an update from the Infectious Diseases Society of America", Clin Infect Dis, 56, pp.1685~1694 (2013)

관련 논문AI추천